Novan Further Expands its Proprietary Nitric Oxide Platform
- A new product candidate, SB207, to target anti-viral opportunities
- Pre-IND meeting anticipated in December 2019
- Development of SB207 to be focused on indications with unmet patient need, such as external genital warts
MORRISVILLE, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has submitted a request for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for new product candidate, SB207. The Company anticipates that the meeting will be held in December 2019.